Lohit Kumar Kalita1, Chayanika Kalita2, Pabitra Kumar Gogai3, Umesh Ch. Sarma4
Multiple myeloma is a rare cancer. According to the most recent data from the Surveillance, Epidemiology, and End Results (SEER) program, multiple myeloma is the second most common haematological malignancy in the U.S. (after non-Hodgkin lymphoma), constitutes 1% of all cancers and constitutes 2% of all cancer deaths. Cutaneous involvement of multiple myeloma during treatment period is uncommon with fewer described in literature. Moreover, metastatic cutaneous involvement at the sole of the foot during treatment period of a IgA kappa type multiple myeloma patient followed by death has not encountered in literature. We have reported such a case.
